Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (53)

Advertisement

Research Article Free access | 10.1172/JCI113528

Impaired cardiac muscarinic receptor function in dogs with heart failure.

D E Vatner, D L Lee, K R Schwarz, J P Longabaugh, A M Fujii, S F Vatner, and C J Homcy

Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114.

Find articles by Vatner, D. in: JCI | PubMed | Google Scholar

Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114.

Find articles by Lee, D. in: JCI | PubMed | Google Scholar

Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114.

Find articles by Schwarz, K. in: JCI | PubMed | Google Scholar

Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114.

Find articles by Longabaugh, J. in: JCI | PubMed | Google Scholar

Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114.

Find articles by Fujii, A. in: JCI | PubMed | Google Scholar

Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114.

Find articles by Vatner, S. in: JCI | PubMed | Google Scholar

Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114.

Find articles by Homcy, C. in: JCI | PubMed | Google Scholar

Published June 1, 1988 - More info

Published in Volume 81, Issue 6 on June 1, 1988
J Clin Invest. 1988;81(6):1836–1842. https://doi.org/10.1172/JCI113528.
© 1988 The American Society for Clinical Investigation
Published June 1, 1988 - Version history
View PDF
Abstract

Prior physiological studies have suggested that parasympathetic control is altered in heart failure. The goal of our studies was to investigate the influence of heart failure on the muscarinic receptor, and its coupling to adenylate cyclase. Ligand binding studies using [3H]quinuclidinyl benzilate and enriched left ventricular (LV) sarcolemma, demonstrated that muscarinic receptor density in heart failure declined 36% from a control of 5.6 +/- 0.6 pmol/mg, with no change in antagonist affinity. However, agonist competition studies with both carbachol and oxotremorine showed that it was a loss of high affinity agonist binding sites in the sarcolemma from failing LV that accounted for this difference. The functional efficacy of the muscarinic receptor was also examined. When 1 microM methacholine was added to 0.1 mM GTP and 0.1 mM isoproterenol, adenylate cyclase stimulated activity was inhibited by 15% in normal LV but only 5% in LV sarcolemma from animals with heart failure even when the reduced adenylate cyclase in these heart failure animals was taken into account. Even at 100-fold greater concentrations of methacholine, significantly less inhibition of adenylate cyclase activity was observed in LV failure as compared with normal LV sarcolemma. Levels of the GTP-inhibitory protein known to couple the muscarinic receptor to adenylate cyclase, as measured with pertussis toxin labeling, were not depressed in LV failure. Thus, the inhibitory pathway regulating LV adenylate cyclase activity is defective in heart failure. The decrease in muscarinic receptor density, and in particular the specific loss of the high affinity agonist binding component of this receptor population, appears to be the major factor underlying this abnormality.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1836
page 1836
icon of scanned page 1837
page 1837
icon of scanned page 1838
page 1838
icon of scanned page 1839
page 1839
icon of scanned page 1840
page 1840
icon of scanned page 1841
page 1841
icon of scanned page 1842
page 1842
Version history
  • Version 1 (June 1, 1988): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (53)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts